Home / CCL5/RANTES / Human/Primate CCL5/RANTES Biotinylated Antibody

Human/Primate CCL5/RANTES Biotinylated Antibody

Catalog #: BAF278
32 Citations 1 Review Datasheet / COA / SDS
Catalog # Availability Size / Price Qty
BAF278
Detection of Human CCL5/RANTES by ELISA
2 Images
Product Details
Citations (32)
FAQs
Supplemental Products
Reviews (1)
Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human/Primate CCL5/RANTES Biotinylated Antibody Summary

Species Reactivity
Human, Primate
Specificity
Detects human and primate CCL5/RANTES in ELISAs and Western blots.  In sandwich immunoassays, approximately 12% cross‑reactivity with rmCCL5 is observed and less than 0.05% cross‑reactivity with rhIL-8, rhGRO alpha, rhMCP-1, rhMIP-1 alpha and rhMIP‑1 beta is observed.
Source
Polyclonal Goat IgG
Purification
Antigen Affinity-purified
Immunogen
E. coli-derived recombinant human CCL5/RANTES
Ser24-Ser91
Accession # P13501
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Label
Biotin

Applications

Recommended Concentration
Sample
Western Blot
0.1 µg/mL
Recombinant Human CCL5/RANTES (Catalog # 278-RN)

Human/Primate CCL5/RANTES Sandwich Immunoassay

Recommended Concentration
Reagent
ELISA Detection (Matched Antibody Pair)
0.1-0.4 µg/mL 

Use in combination with:

Capture Reagent: Human/Primate CCL5/RANTES Antibody (Catalog # MAB678)

Standard: Recombinant Human CCL5/RANTES Protein (Catalog # 278-RN)

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

ELISA Detection of Human CCL5/RANTES by ELISA View Larger

Detection of Human CCL5/RANTES by ELISA Impact of prolonged stimulation by Tumor CM on the release of inflammatory chemokines by the resulting CAFs. Human BM-derived MSCs were cultured with Tumor CM from MDA-MB-231 cells (MDA) (A) or MCF-7 cells (B) over a prolonged period of time (~30 days; MSCs + MDA CM or MSCs + MCF-7 CM, respectively). Twenty-four hours after medium exchange to fresh Tumor CM, cell supernatants were collected and the expression of CCL2 (A1, B1), CXCL8 (A2, B2) and CCL5 (A3, B3) was determined in comparison with supernatants of MSCs that were not supplemented with CM (MSCs) and with the original Tumor CM of MDA-MB-231 or MCF-7 cells alone (MDA CM or MCF-7 CM, respectively). Chemokine expression was determined by ELISA, in the linear range of absorbance. (A1), (A2), (B1) Representatives of n = 3 independent experiments that have shown similar results. (A3), (B2), (B3) Ratios between MSCs and MSCs + Tumor CM were not consistent in different experimental repeats. Therefore, in these panels, the findings are presented as mean ± standard deviation of normalized values (MSCs were given the value of 1) obtained in relevant experimental repeats (at least n = 3). Image collected and cropped by CiteAb from the following publication (https://stemcellres.biomedcentral.com/articles/10.1186/s13287-015-0080-7), licensed under a CC-BY license. Not internally tested by R&D Systems.

ELISA Detection of Human CCL5/RANTES by ELISA View Larger

Detection of Human CCL5/RANTES by ELISA Basal and cytokine-induced release of inflammatory chemokines by patient CAFs. CAFs were isolated from lung metastasis of a breast cancer patient (CAFs #1) or from a primary tumor of a different breast cancer patient (CAFs #2). (A1, B1) Expression of the pro-malignancy chemokines CCL2, CXCL8 and CCL5 was determined by ELISA, in the linear range of absorbance. (A2, B2) Expression of CCL5 was determined following TNFa and IL-1 beta stimulation (TNF-alpha, 50 ng/ml; IL-1 beta, 500 pg/ml; 48 hours). Control cells were stimulated by vehicle. Expression of the chemokines was determined by ELISA, in the linear range of absorbance. In all panels, the findings are representatives of at least n = 3 independent experiments that have shown similar results. Image collected and cropped by CiteAb from the following publication (https://stemcellres.biomedcentral.com/articles/10.1186/s13287-015-0080-7), licensed under a CC-BY license. Not internally tested by R&D Systems.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Preparation and Storage

Reconstitution
Reconstitute at 0.2 mg/mL in sterile PBS.
Loading...
Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CCL5/RANTES

CCL5, also known as RANTES (Regulated upon Activation, Normal T cell Expressed and presumably Secreted), is an 8 kDa beta -chemokine that plays a primary role in the inflammatory immune response by means of its ability to attract and activate leukocytes (1 - 3). Human and mouse RANTES exhibit cross-species activity on human and mouse cells (4). Mature human CCL5 shares 75% - 84% aa seqeuence identity with canine, cotton rat, feline, mouse, and rat CCL5 (5). CCL5 is secreted by many cell types at inflammatory sites, and it exerts a wide range of activities through the receptors CCR1, CCR3, CCR4, and CCR5 (6, 7). Inflammatory responses can be impaired by the sequestration of CCL5 by the cytomegalovirus protein US28 (8). In humans, CCR5 binding to CCL5 inhibits the infectivity of R5 (M-tropic) but not X4 (T-tropic) strains of HIV-1 (9). The two N-terminal residues of CCL5 can be removed by CD26/DPPIV, generating a protein that functions as a chemotaxis inhibitor and more effectively blocks M-tropic HIV-1 infection of monocytes (10). Oligomerization of CCL5 on glycosaminoglycans is required for CCR1-mediated leukocyte adhesion and activation as well as CCL5’s interaction with the chemokine CXCL4/PF4 (11 - 13). The deposition of CCL5 on activated vascular endothelial cells is crucial for monocyte adhesion to damaged vasculature, but CCL5 oligomerization is not required for the extravasation of adherent leukocytes (14 - 16). CCL5 is upregulated in breast cancer and promotes tumor progression through the attraction of proinflammatory macrophages in addition to its actions on tumor cells, stromal cells, and the vasculature (17).

References
  1. Schall, T.J. et al. (1990) Nature 347:669.
  2. Bacon, K.B. et al. (1995) Science 269:1727.
  3. Fischer, F.R. et al. (2001) J. Immunol. 167:1637.
  4. Schall, T.J. et al. (1992) Eur. J. Immunol. 22:1477.
  5. Schall, T.J. et al. (1988) J. Immunol. 141:1018.
  6. Appay, V. and S.L. Rowland-Jones (2001) Trends Immunol. 22:83.
  7. Levy, J.A. (2009) J. Immunol. 182:3945.
  8. Randolph-Habecker, J.R. et al. (2002) Cytokine 19:37.
  9. DeVico, A.L. and Gallo, R.C. (2004) Nat. Rev. Microbiol. 2:401.
  10. Proost, P. et al. (1998) J. Biol. Chem. 273:7222.
  11. Appay, V. et al. (1999) J. Biol. Chem. 274:27505.
  12. Proudfoot, A.E.I. et al. (2003) Proc. Natl. Acad. Sci. 100:1885.
  13. von Hundelshausen, P. et al. (2005) Blood 105:924.
  14. von Hundelshausen, P. et al. (2001) Circulation 103:1772.
  15. Zernecke, A. et al. (2008) Arterioscler. Thromb. Vasc. Biol. 28:1897.
  16. Baltus, T. et al. (2003) Blood 102:1985.
  17. Soria, G. and A. Ben-Baruch (2008) Cancer Lett. 267:271.
Entrez Gene IDs
6352 (Human); 20304 (Mouse); 403522 (Canine); 493689 (Feline)
Alternate Names
CCL5; chemokine (C-C motif) ligand 5; D17S136Enormally T-expressed, and presumably secreted; EoCP; Eosinophil chemotactic cytokine; RANTES; SISd; SIS-delta; small inducible cytokine A5 (RANTES); small inducible cytokine subfamily A (Cys-Cys), member 5; Small-inducible cytokine A5; T cell-specific protein P228; T-cell specific protein p288; TCP228T-cell-specific protein RANTES

Product Datasheets

You must select a language.

x
Product Datasheet
COA
SDS

Citations for Human/Primate CCL5/RANTES Biotinylated Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

32 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. The Global Phosphorylation Landscape of SARS-CoV-2 Infection
    Authors: Mehdi Bouhaddou, Danish Memon, Bjoern Meyer, Kris M. White, Veronica V. Rezelj, Miguel Correa Marrero et al.
    Cell
  2. Notch-Mediated Tumor-Stroma-Inflammation Networks Promote Invasive Properties and CXCL8 Expression in Triple-Negative Breast Cancer
    Authors: Yulia Liubomirski, Shalom Lerrer, Tsipi Meshel, Dina Morein, Linor Rubinstein-Achiasaf, David Sprinzak et al.
    Frontiers in Immunology
  3. Tumor-Stroma-Inflammation Networks Promote Pro-metastatic Chemokines and Aggressiveness Characteristics in Triple-Negative Breast Cancer
    Authors: Yulia Liubomirski, Shalom Lerrer, Tsipi Meshel, Linor Rubinstein-Achiasaf, Dina Morein, Stefan Wiemann et al.
    Frontiers in Immunology
  4. A Gel-Based Dual Antibody Capture and Detection Method for Assaying of Extracellular Cytokine Secretion: EliCell
    Authors: Lisa A. Spencer, Rossana C. N. Melo, Sandra A. C. Perez, Peter F. Weller
    Handbook of ELISPOT
  5. A scalable low-cost cGMP process for clinical grade production of the HIV inhibitor 5P12-RANTES in Pichia pastoris
    Authors: Fabrice Cerini, Hubert Gaertner, Knut Madden, Ilya Tolstorukov, Scott Brown, Bram Laukens et al.
    Protein Expression and Purification
  6. Effect of teriparatide on drug treatment of tuberculous spondylitis: an experimental study
    Authors: S Lee, YJ Seo, JY Choi, X Che, HJ Kim, SY Eum, MS Hong, SK Lee, DC Cho
    Scientific Reports, 2022-12-15;12(1):21667.
    Species: Human
    Sample Types: Cell Culture Supernates
    Applications: ELISA Detection
  7. Development of an Electrochemical CCL5 Chemokine Immunoplatform for Rapid Diagnosis of Multiple Sclerosis
    Authors: S Guerrero, E Sánchez-Ti, L Agüí, A González-C, P Yáñez-Sede, JM Pingarrón
    Biosensors, 2022-08-07;12(8):.
    Species: Human
    Sample Types: Serum
    Applications: ELISA Capture
  8. Inflammation-Driven Regulation of PD-L1 and PD-L2, and Their Cross-Interactions with Protective Soluble TNFalpha Receptors in Human Triple-Negative Breast Cancer
    Authors: T Baram, N Oren, N Erlichman, T Meshel, A Ben-Baruch
    Cancers, 2022-07-19;14(14):.
    Species: Human
    Sample Types: Cell Culture Supernates
    Applications: ELISA Capture
  9. Tumor Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Human Breast Cancer Are Mediated by PD-L1-S283 and Chemokine Axes
    Authors: N Erlichman, T Baram, T Meshel, D Morein, B Da'adoosh, A Ben-Baruch
    Cancers, 2022-02-18;14(4):.
    Species: Human
    Sample Types: Cell Culture Supernates
    Applications: ELISA Detection
  10. Immune-Stimulatory Effects of Curcumin on the Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma
    Authors: C Kötting, L Hofmann, R Lotfi, D Engelhardt, S Laban, PJ Schuler, TK Hoffmann, C Brunner, MN Theodoraki
    Cancers, 2021-03-16;13(6):.
    Species: Human
    Sample Types: Cell Culture Supernates
    Applications: ELISA Detection
  11. T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers
    Authors: PS Arunachala, TP Charles, V Joag, VS Bollimpell, MKD Scott, F Wimmers, SL Burton, CC Labranche, C Petitdeman, S Gangadhara, TM Styles, CF Quarnstrom, KA Walter, TJ Ketas, T Legere, PB Jagadeesh, SP Kasturi, A Tsai, BZ Yeung, S Gupta, M Tomai, J Vasilakos, GM Shaw, CY Kang, JP Moore, S Subramania, P Khatri, D Montefiori, PA Kozlowski, CA Derdeyn, E Hunter, D Masopust, RR Amara, B Pulendran
    Nat. Med., 2020-05-11;0(0):.
    Species: Human
    Sample Types: Cell Culture Supernates
    Applications: ELISA Detection
  12. Biological and Clinical Significance of the CCR5/CCL5 Axis in Hepatocellular Carcinoma
    Authors: SK Singh, MK Mishra, BM Rivers, JB Gordetsky, S Bae, R Singh
    Cancers (Basel), 2020-04-05;12(4):.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC
  13. Oligomerized, filamentous surface presentation of RANTES/CCL5 on vascular endothelial cells.
    Authors: Oynebraten I, Barois N, Bergeland T, Kuchler A, Bakke O, Haraldsen G
    Sci Rep, 2015-03-20;5(0):9261.
    Species: Human
    Sample Types: Whole Cells
    Applications: ICC
  14. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice.
    Authors: Koenen RR, von Hundelshausen P, Nesmelova IV, Zernecke A, Liehn EA, Sarabi A, Kramp BK, Piccinini AM, Paludan SR, Kowalska MA, Kungl AJ, Hackeng TM, Mayo KH, Weber C
    Nat. Med., 2009-01-04;15(1):97-103.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  15. Maternal and cord plasma cytokine and chemokine profile in pregnancies complicated by asthma.
    Authors: Osei-Kumah A, Smith R, Clifton VL
    Cytokine, 2008-07-17;43(2):187-93.
    Species: Human
    Sample Types: Plasma
    Applications: ELISA Development
  16. Relation of circulating concentrations of chemokine receptor CCR5 ligands to C-peptide, proinsulin and HbA1c and disease progression in type 1 diabetes.
    Authors: Pfleger C, Kaas A, Hansen L, Alizadeh B, Hougaard P, Holl R, Kolb H, Roep BO, Mortensen HB, Schloot NC
    Clin. Immunol., 2008-04-22;128(1):57-65.
    Species: Human
    Sample Types: Serum
    Applications: ELISA Development
  17. Development and validation of sandwich ELISA microarrays with minimal assay interference.
    Authors: Gonzalez RM, Seurynck-Servoss SL, Crowley SA
    J. Proteome Res., 2008-04-19;7(6):2406-14.
    Species: Human
    Sample Types: Serum
    Applications: ELISA Microarray Development
  18. Upregulation of human cytomegalovirus by HIV type 1 in human lymphoid tissue ex vivo.
    Authors: Biancotto A, Iglehart SJ, Lisco A, Vanpouille C, Grivel JC, Lurain NS, Reichelderfer PS, Margolis LB
    AIDS Res. Hum. Retroviruses, 2008-03-01;24(3):453-62.
    Species: Human
    Sample Types: Cell Culture Supernates
    Applications: Luminex Development
  19. Fluorescence single-molecule counting assays for high-sensitivity detection of cytokines and chemokines.
    Authors: Qui H, Ferrell EP, Nolan N, Phelps BH, Tabibiazar R, Whitney DH, Naelfski EA
    Clin. Chem., 2007-11-01;53(11):2010-2.
    Species: Human
    Sample Types: Plasma
    Applications: ELISA Development
  20. Ultrasensitive flow-based immunoassays using single-molecule counting.
    Authors: Todd J, Freese B, Lu A, Held D, Morey J, Livingston R, Goix P
    Clin. Chem., 2007-09-21;53(11):1990-5.
    Species: Human
    Sample Types: Plasma
    Applications: ELISA Development
  21. Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1.
    Authors: Biancotto A, Grivel JC, Iglehart SJ, Vanpouille C, Lisco A, Sieg SF, Debernardo R, Garate K, Rodriguez B, Margolis LB, Lederman MM
    Blood, 2007-02-08;109(10):4272-9.
    Species: Human
    Sample Types: Cell Culture Supernates
    Applications: Luminex Development
  22. HIV-1 pathogenesis differs in rectosigmoid and tonsillar tissues infected ex vivo with CCR5- and CXCR4-tropic HIV-1.
    Authors: Grivel JC, Elliott J, Lisco A, Biancotto A, Condack C, Shattock RJ, McGowan I, Margolis L, Anton P
    AIDS, 2007;21(10):1263-72.
    Species: Human
    Sample Types: Cell Culture Supernates
    Applications: Luminex Development
  23. Transforming growth factor beta 1(TGF-beta1) down-regulates TNFalpha-induced RANTES production in rheumatoid synovial fibroblasts through NF-kappaB-mediated transcriptional repression.
    Authors: Cho ML, Min SY, Chang SH, Kim KW, Heo SB, Lee SH, Park SH, Cho CS, Kim HY
    Immunol. Lett., 2006-03-03;105(2):159-66.
    Species: Human
    Sample Types: Cell Culture Supernates
    Applications: ELISA Development
  24. Combination therapy: Synergistic suppression of virus-induced chemokines in airway epithelial cells.
    Authors: Edwards MR, Johnson MW, Johnston SL
    Am. J. Respir. Cell Mol. Biol., 2006-01-19;34(5):616-24.
    Species: Human
    Sample Types: Cell Culture Supernates
    Applications: ELISA Development
  25. Changes in soluble factor-mediated CD8+ cell-derived antiviral activity in cynomolgus macaques infected with simian immunodeficiency virus SIVmac251: relationship to biological markers of progression.
    Authors: Dioszeghy V, Benlhassan-Chahour K, Delache B, Dereuddre-Bosquet N, Aubenque C, Gras G, Le Grand R, Vaslin B
    J. Virol., 2006-01-01;80(1):236-45.
    Species: Primate - Macaca fascicularis (Crab-eating Monkey or Cynomolgus Macaque)
    Sample Types: Cell Culture Supernates
    Applications: ELISA Development
  26. Rapid chemokine secretion from endothelial cells originates from 2 distinct compartments.
    Authors: Oynebraten I, Bakke O, Brandtzaeg P, Johansen FE, Haraldsen G
    Blood, 2004-03-25;104(2):314-20.
    Species: Human
    Sample Types: Whole Cells
    Applications: ICC
  27. Secretion of oncostatin M by infiltrating neutrophils: regulation of IL-6 and chemokine expression in human mesothelial cells.
    Authors: Hurst SM, McLoughlin RM, Monslow J, Owens S, Morgan L, Fuller GM, Topley N, Jones SA
    J. Immunol., 2002-11-01;169(9):5244-51.
    Species: Human
    Sample Types: Cell Culture Supernates
    Applications: ELISA Development
  28. Selective induction of eotaxin release by interleukin-13 or interleukin-4 in human airway smooth muscle cells is synergistic with interleukin-1beta and is mediated by the interleukin-4 receptor alpha-chain.
    Authors: Hirst SJ, Hallsworth MP, Peng Q
    Am. J. Respir. Crit. Care Med., 2002-04-15;165(8):1161-71.
    Species: Human
    Sample Types: Cell Culture Supernates
    Applications: ELISA Development
  29. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation.
    Authors: Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, Rose-John S, Fuller GM, Topley N, Jones SA
    Immunity, 2001-06-01;14(6):705-14.
    Species: Human
    Sample Types: Cell Culture Supernates
    Applications: ELISA Development
  30. Chemoattractant factors in breast milk from allergic and nonallergic mothers.
    Authors: Bottcher MF, Jenmalm MC, Bjorksten B, Garofalo RP
    Pediatr. Res., 2000-05-01;47(5):592-7.
    Species: Human
    Sample Types: Serum
    Applications: ELISA Development
  31. Regulation of the inflammatory profile of stromal cells in human breast cancer: prominent roles for TNF-alpha and the NF-kappa B pathway
    Authors: Christina Katanov, Shalom Lerrer, Yulia Liubomirski, Leonor Leider-Trejo, Tsipi Meshel, Jair Bar et al.
    Stem Cell Research & Therapy
  32. Tumor-Promoting Circuits That Regulate a Cancer-Related Chemokine Cluster: Dominance of Inflammatory Mediators Over Oncogenic Alterations
    Authors: Tal Leibovich-Rivkin, Yosef Buganim, Hilla Solomon, Tsipi Meshel, Varda Rotter, Adit Ben-Baruch
    Cancers (Basel)

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs
Loading...

Reviews for Human/Primate CCL5/RANTES Biotinylated Antibody

Average Rating: 4 (Based on 1 Review)

5 Star
0%
4 Star
100%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Human/Primate CCL5/RANTES Biotinylated Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Human/Primate CCL5/RANTES Biotinylated Antibody
By Anonymous on 11/22/2017
Application: ELISA Sample Tested: Serum and Plasma Species: Human

The RANTES ELISA we made used MAG678 as the capture and BAF278 as the detection. Dilutional linearity of samples wasn't great but otherwise the assay worked very well.

ELISA Human/Primate CCL5/RANTES Biotinylated Antibody BAF278